AA amyloidosis in a polyarteritis nodosa patient treated with tocilizumab

Abstract Amyloid A (AA) (secondary) amyloidosis represents a severe complication of chronic inflammatory diseases. Since pathogenic mechanisms point to the central role of interleukin 6 (IL-6) in the process of amyloid AA generation, IL-6 blockade seems an attractive therapeutic option. We report a...

Full description

Saved in:

Bibliographic Details
Published in:	Amyloid Vol. 20; no. 4; pp. 275 - 276
Main Authors:	Ho evar, Alojzija, Lestan, Boris, Sodin Šemrl, Sne na, Lakota, Katja, Kojc, Nika, Poto nik, Nataša, Tomši, Matija
Format:	Journal Article
Language:	English
Published:	England Informa UK Ltd 01-12-2013
Subjects:	Adult Amyloidosis - drug therapy Amyloidosis - metabolism Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - therapeutic use Humans Methylprednisolone - administration & dosage Methylprednisolone - therapeutic use Polyarteritis Nodosa - drug therapy Polyarteritis Nodosa - metabolism Serum Amyloid A Protein - metabolism
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Amyloid A (AA) (secondary) amyloidosis represents a severe complication of chronic inflammatory diseases. Since pathogenic mechanisms point to the central role of interleukin 6 (IL-6) in the process of amyloid AA generation, IL-6 blockade seems an attractive therapeutic option. We report a case of a patient with polyarteritis nodosa complicated by AA amyloidosis treated with tocilizumab.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	1350-6129 1744-2818
DOI:	10.3109/13506129.2013.838947